Raptor Pharmaceuticals Provides Update of Produc...(sion of regulatoryfilings for marketing ...),Health

Donna Kato, the CEO of Regulatory Professionals, Inc. stated, "We are very excited to be working with Raptor as it advances toward clinical trials."

Dr. Christopher Starr, Raptor's CEO stated, "Building an internal team of high-quality individuals would take a great deal of time and money, while Donna and her team provide us access to the best talent under a tight development timeline and operational flexibility essential to an emerging company." More information on Regulatory Professionals, Inc. can be found on their website http://www.regprofessional.com.

In addition, Raptor has initiated proof-of-principle preclinical studies targeting a new therapeutic area: the use of the HepTide delivery molecule to enhance the distribution of antiviral drugs to the liver for the treatment of viral hepatitis. HepTide has shown strong hepatotrophic activity by binding selectively to liver cells or to infected liver cells in preclinical studies. Conjugates of HepTide and antiviral agents could significantly improve accumulation of these agents in the liver and reduce the amount of powerful antiviral agents elsewhere in the body.

Stanford University Grant Renewed for NeuroTrans(TM) in Neurodegenerative Diseases

Based on promising early results in blood-brain barrier ("BBB") transport models from its collaboration initiated in August 2006, Raptor has renewed its grant with Dr. William Mobley's neuroscience laboratory at Stanford University. In the first year of the collaboration, a number of RAP peptides were tested for their ability to cross the BBB. From these experiments, the team selected a lead candidate transport peptide called RAP-2s. In this second year, the team will continue to assess the bio-distribution of RAP-2s within various brain compartments, commence testing of RAP-2s' ability to deliver Nerve Growth Factor ("NGF") across the
'/>"/>